70.84
+3.27%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Tarsus Pharmaceuticals
From its filings with the US Securities and Exchange Commission
Tarsus Pharmaceuticals is based in Irvine, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker TARS. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $451.4m and a net loss of $66.4m. At that date it held total assets of $562.2m and shareholders' equity of $343.4m.
We are a commercial stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. We launched XDEMVY® (lotilaner ophthalmic solution) 0.25%, formerly known as TP-03, for the treatment of Demodex blepharitis, in August 2023 after receiving U.S. Food and Drug Administration (“FDA”) approval in July 2023. Demodex blepharitis is caused by the infestation of Demodex mites. Demodex blepharitis (“blephar” is a reference to eyelid and “itis” is a reference to inflammation) is a disease characterized by inflammation of the eyelid margin, redness and ocular irritation, including a specific type of eyelash dandruff called collarettes, which are pathognomonic for Demodex blepharitis. Poorly controlled and progressive Demodex blepharitis can lead to corneal damage over time and, in extreme cases, blindness. There may be as many as approximately 25 million people in the U.S. who suffer from Demodex blepharitis. XDEMVY is the first and only therapeutic approved by the FDA and we believe is the definitive standard of care for the treatment of Demodex blepharitis.
Quoted from its 10-K, filed 23 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 16 Oct 2020
- Employees
- 370
- Website
- tarsusrx.com ↗
- Head office
- 15440 LAGUNA CANYON ROAD, IRVINE, CA, 92618
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Bobak AzamianChairman of the Board, President, Chief Executive Officer, Co-Founder, since 2016$7.9m
- Mr. Jeffrey FarrowChief Financial Officer and Chief Strategy Officer$3.2m
- Dr. Seshadri NeervannanChief Operating Officer$3.2m
- Ms. Dianne WhitfieldChief Human Resources Officer$3.2m
- Dr. Bryan WahlGeneral Counsel, Secretary$2.5m
- Mr. Aziz MottiwalaChief Commercial Officer$3.1m
- Dr. Elizabeth YeuChief Medical Officer, since 2021$3.1m
- Ms. Wendy YarnoLead Independent Director$367,854
- Dr. Bhaskar ChaudhuriIndependent Director$280,536
- Dr. Andrew GoldbergIndependent Director$271,854
- Dr. Katherine GoodrichIndependent Director$635,695
- Dr. William LinkIndependent Director$284,354
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 32
- Environment
- 35
- Social
- 23
- Governance
- 36
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Tarsus Pharmaceuticals Inc has several strengths that contribute to its success:
Weaknesses
- Although Tarsus Pharmaceuticals Inc is a thriving company, it also faces certain weaknesses:
Opportunities
- Tarsus Pharmaceuticals Inc can take advantage of the following opportunities to drive growth:
Threats
- Tarsus Pharmaceuticals Inc should be wary of the following threats that may hinder its progress:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.